Novartis Phase 3 Canopy-A Trial Didn't Meet Primary Endpoint
15 Agosto 2022 - 01:05AM
Noticias Dow Jones
By Kim Richters
Novartis AG's Phase 3 Canopy-A study for canakinumab as adjuvant
treatment in non-small cell lung cancer didn't meet the primary
endpoint of disease-free survival versus placebo.
The Swiss pharmaceutical company said Monday that it will
present findings from the study, which concerned patients with
stages II-IIIA and IIIB completely resected non-small cell lung
cancer, at an upcoming medical meeting.
Write to Kim Richters at kim.richters@wsj.com
(END) Dow Jones Newswires
August 15, 2022 01:50 ET (05:50 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Gráfica de Acción Histórica
De Oct 2023 a Nov 2023
Novartis (NYSE:NVS)
Gráfica de Acción Histórica
De Nov 2022 a Nov 2023
